FR11C0036I1 - SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL - Google Patents

SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL

Info

Publication number
FR11C0036I1
FR11C0036I1 FR11C0036C FR11C0036C FR11C0036I1 FR 11C0036 I1 FR11C0036 I1 FR 11C0036I1 FR 11C0036 C FR11C0036 C FR 11C0036C FR 11C0036 C FR11C0036 C FR 11C0036C FR 11C0036 I1 FR11C0036 I1 FR 11C0036I1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
compositions containing
receptor agonist
sugar alcohol
solid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0036C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Tanabe Seiyaku Co Ltd
Original Assignee
Novartis AG
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Tanabe Seiyaku Co Ltd filed Critical Novartis AG
Publication of FR11C0036I1 publication Critical patent/FR11C0036I1/en
Application granted granted Critical
Publication of FR11C0036I2 publication Critical patent/FR11C0036I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
FR11C0036C 2003-04-08 2011-09-08 SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL Active FR11C0036I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Publications (2)

Publication Number Publication Date
FR11C0036I1 true FR11C0036I1 (en) 2011-10-14
FR11C0036I2 FR11C0036I2 (en) 2023-12-29

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (en) 2003-04-08 2004-04-06 SOLID PHARMACEUTICAL COMPOSITION COMPRISING S1P RECEPTOR AGONIST AND SUGAR ALCOHOL
FR11C0036C Active FR11C0036I2 (en) 2003-04-08 2011-09-08 SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (en) 2003-04-08 2004-04-06 SOLID PHARMACEUTICAL COMPOSITION COMPRISING S1P RECEPTOR AGONIST AND SUGAR ALCOHOL

Country Status (42)

Country Link
US (11) US20060275357A1 (en)
EP (5) EP2319502A1 (en)
JP (3) JP5495467B2 (en)
KR (3) KR20110005320A (en)
CN (2) CN1767819B (en)
AR (3) AR043987A1 (en)
AT (3) AT501681B1 (en)
AU (1) AU2004228929B2 (en)
BE (2) BE1015972A5 (en)
BR (1) BRPI0409250B8 (en)
CA (2) CA2521325C (en)
CL (2) CL2004000745A1 (en)
CY (3) CY1110260T1 (en)
DE (4) DE202004021680U1 (en)
DK (2) DK2316431T3 (en)
EC (1) ECSP056090A (en)
ES (3) ES2228282B1 (en)
FR (2) FR2854073B1 (en)
GB (1) GB2400318B (en)
GR (1) GR1005052B (en)
HK (3) HK1071685A1 (en)
HR (3) HRP20050886B1 (en)
HU (2) HUE028247T2 (en)
IL (3) IL170888A (en)
IS (2) IS2682B (en)
IT (1) ITMI20040682A1 (en)
LU (1) LU91867I2 (en)
MA (1) MA27729A1 (en)
MX (1) MXPA05010860A (en)
MY (1) MY141249A (en)
NO (4) NO329332B1 (en)
NZ (3) NZ542622A (en)
PE (5) PE20090743A1 (en)
PL (2) PL1613288T3 (en)
PT (1) PT1613288E (en)
RU (5) RU2358716C2 (en)
SG (1) SG175449A1 (en)
SI (2) SI2316431T1 (en)
TN (1) TNSN05256A1 (en)
TW (1) TWI332847B (en)
WO (1) WO2004089341A1 (en)
ZA (1) ZA200507394B (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096972A1 (en) * 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (en) * 2005-07-07 2010-10-13 马启明 Oral preparation and its preparing method
WO2007028821A2 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
TWI389683B (en) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2007261345B2 (en) 2006-06-19 2012-02-23 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
CN102579387A (en) * 2006-09-26 2012-07-18 诺瓦提斯公司 Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
NZ579725A (en) * 2007-03-29 2012-02-24 Daiichi Sankyo Co Ltd Tablet composition having improved dissolution property
ME02462B (en) 2007-10-04 2017-02-20 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
TW200927142A (en) 2007-10-12 2009-07-01 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (en) * 2008-01-11 2014-07-02 日医工株式会社 Oral dosage formulation containing sarpogrelate hydrochloride with excellent stability in an unwrapped state
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
HUE033168T2 (en) 2008-03-17 2017-11-28 Actelion Pharmaceuticals Ltd Dosing regimen for a selective sip1 receptor agonist
TR201808694T4 (en) * 2008-06-20 2018-07-23 Merck Patent Gmbh Direct compressible and fast disintegrating tablet matrix.
KR20110020928A (en) 2008-06-20 2011-03-03 노파르티스 아게 Paediatric compositions for treating multiple sclerosis
ES2377869T3 (en) * 2008-09-04 2012-04-02 Cargill, Incorporated Erythritol tablet manufacturing
JP5675629B2 (en) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Combination therapy using peptide epoxyketone
US8680146B2 (en) 2008-11-11 2014-03-25 Novartis Ag Organic compounds
CN107233336A (en) * 2008-11-11 2017-10-10 诺华股份有限公司 The crystal form of FTY720
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
RU2464271C1 (en) 2008-12-17 2012-10-20 Дайити Санкио Компани, Лимитед Method of producing diamine derivative
JPWO2010082531A1 (en) 2009-01-13 2012-07-05 第一三共株式会社 Activated blood coagulation factor inhibitor
CN102348688B (en) 2009-03-10 2014-07-09 第一三共株式会社 Process for producing diamine derivative
JP5652879B2 (en) 2009-03-13 2015-01-14 第一三共株式会社 Method for producing optically active diamine derivative
TWI504598B (en) 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide epoxy ketone protease inhibitors
TW201102064A (en) * 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
KR20130075723A (en) 2010-03-01 2013-07-05 오닉스 세라퓨틱스, 인크. Compounds for immunoproteasome inhibition
WO2011115067A1 (en) 2010-03-19 2011-09-22 第一三共株式会社 Method for improving dissolvability of anticoagulant
CN102791719B (en) 2010-03-19 2015-07-29 第一三共株式会社 Crystal of diamine derivative and preparation method thereof
US20130095177A1 (en) * 2010-04-22 2013-04-18 Ratiopharm Gmbh Method of preparing an oral dosage form comprising fingolimod
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd Fingolimod polymorphs and their processes
DK2665471T3 (en) 2011-01-19 2018-03-19 Pathologica Llc ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG
AR085749A1 (en) * 2011-04-01 2013-10-23 Novartis Ag FORMULATIONS
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
KR101940840B1 (en) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 Pharmaceutical composition containing diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (en) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Pharmaceutical composition of s1p receptor agonist for treatment of demyelinating diseases (versions) and method of its obtaining
RU2506949C1 (en) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Pharmaceutical composition of sip receptor agonist for treating demyeliniating diseases
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (en) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Pharmaceutical composition exhibiting improved flowability, drug preparation, method for preparing and using
US10085955B2 (en) 2013-01-08 2018-10-02 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (en) * 2013-04-26 2014-10-30 国立大学法人 京都大学 Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same
MX370184B (en) * 2013-05-13 2019-12-04 Synthon Bv Pharmaceutical composition comprising fingolimod.
MX2016001422A (en) * 2013-07-29 2016-10-05 Aizant Drug Res Solutions Pvt Ltd Pharmaceutical compositions of fingolimod.
RU2530626C1 (en) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Pharmaceutical composition of s1p receptor agonist for treating demyeliniating diseases
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
AU2016209466A1 (en) * 2015-01-20 2017-08-10 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (en) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Method of producing capsules of fingolimod hydrochloride
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (en) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Pharmaceutical composition comprising an immunomodulatory agent and method for the preparation thereof
DE102018217334A1 (en) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid base and / or active ingredient for use in the prophylaxis and / or therapy of a viral infection and / or viral infectious disease or disinfection, food / food supplements, feed / feed supplements and crop protection agents
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (en) * 1976-07-12 1978-01-16 Akzo Nv PROCESS FOR PREPARING NEW PEPTIDES AND PEPTIDE DERIVATIVES AND THEIR USE
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (en) * 1990-11-29 1998-12-24 田辺製薬株式会社 Long-term stable oral pharmaceutical preparation
JP2579602B2 (en) 1992-10-21 1997-02-05 吉富製薬株式会社 2-amino-1,3-propanediol compound and immunosuppressant
DE69524962D1 (en) 1994-08-22 2002-02-14 Welfide Corp BENZENE DERIVATIVES AND THEIR MEDICAL USE
ATE279185T1 (en) 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DI L CONTAINING MEDICINAL PRODUCT FOR TOPICAL USE FOR THE TREATMENT OF DISEASES CAUSED BY A DISRUPTION OF THE IMMUNE SYSTEM
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (en) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp Medicinal composition
JPH11209277A (en) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DK0990440T3 (en) * 1997-02-27 2009-02-23 Novartis Ag Pharmaceutical composition containing 2-amino-2 [2- (4-octylphenyl) ethyl] propane-1,3-diol, a lecithin and a saccharide
US6214873B1 (en) * 1997-04-04 2001-04-10 Welfide Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (en) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd New immunosuppressant, its use and its identification
JP3545595B2 (en) 1998-04-01 2004-07-21 花王株式会社 Production method of glycosphingolipid
JP4627356B2 (en) * 1999-06-30 2011-02-09 松森　　昭 Drugs for preventing or treating viral myocarditis
WO2001003739A1 (en) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate
IL153594A0 (en) 2000-07-13 2003-07-06 Sankyo Co Amino alcohol derivatives and pharmaceutical compositions containing the same
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
MXPA03008755A (en) 2001-03-26 2004-02-18 Novartis Ag 2-amino-propanol derivatives.
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (en) 2001-04-20 2002-10-31 Sankyo Co Ltd Benzothiophene derivative
EP1424078A4 (en) 2001-09-04 2009-03-25 Ono Pharmaceutical Co Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
ATE441654T1 (en) 2002-01-18 2009-09-15 Merck & Co Inc EDG RECEPTOR AGONISTS
JP4709488B2 (en) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション N- (benzyl) aminoalkylcarboxylic acid compounds, phosphinic acid compounds, phosphonic acid compounds and tetrazoles as Edg receptor agonists
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
PL1772145T3 (en) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Method of effectively using medicine and method concerning prevention of side effect

Also Published As

Publication number Publication date
US20090203798A1 (en) 2009-08-13
IS8114A (en) 2005-11-01
ZA200507394B (en) 2007-03-28
KR20110005320A (en) 2011-01-17
BE1015972A5 (en) 2005-12-06
CL2011000450A1 (en) 2011-11-25
AT501681B1 (en) 2012-04-15
KR20050121712A (en) 2005-12-27
EP1613288B1 (en) 2008-11-19
KR101367574B1 (en) 2014-02-25
NO329332B1 (en) 2010-09-27
FR11C0036I2 (en) 2023-12-29
ES2228282B1 (en) 2006-02-16
CA2521325C (en) 2010-09-14
HUE028247T2 (en) 2016-12-28
PT1613288E (en) 2009-02-25
PE20050396A1 (en) 2005-07-05
FR2854073A1 (en) 2004-10-29
IL242037A0 (en) 2015-11-30
HRP20100601A2 (en) 2011-03-31
SI2316431T1 (en) 2016-04-29
IS8885A (en) 2010-02-25
JP5495467B2 (en) 2014-05-21
GB2400318B (en) 2005-08-10
NO20100250L (en) 2006-01-09
EP1613288A1 (en) 2006-01-11
AU2004228929A1 (en) 2004-10-21
CY1110260T1 (en) 2014-04-09
FR2854073B1 (en) 2008-03-14
CA2707750A1 (en) 2004-10-21
PE20130200A1 (en) 2013-03-09
RU2009105403A (en) 2010-08-27
US20080311188A1 (en) 2008-12-18
JP5543298B2 (en) 2014-07-09
US20130108675A1 (en) 2013-05-02
US20140255497A1 (en) 2014-09-11
CA2521325A1 (en) 2004-10-21
US20220031609A1 (en) 2022-02-03
AT504853A2 (en) 2008-08-15
CN1767819B (en) 2010-07-28
PE20150676A1 (en) 2015-05-17
NZ586280A (en) 2011-12-22
ATE414508T1 (en) 2008-12-15
CL2004000745A1 (en) 2005-02-11
NO334116B1 (en) 2013-12-16
EP2769713A1 (en) 2014-08-27
TWI332847B (en) 2010-11-11
DE102004016947A1 (en) 2004-10-21
IL197578A (en) 2015-10-29
PE20131352A1 (en) 2013-11-14
DK2316431T3 (en) 2016-01-11
AR043987A1 (en) 2005-08-17
ES2556947T3 (en) 2016-01-21
NO20055231D0 (en) 2005-11-07
PL1613288T3 (en) 2009-07-31
ES2320767T3 (en) 2009-05-28
IL197578A0 (en) 2011-07-31
KR20120101148A (en) 2012-09-12
RU2010146697A (en) 2012-05-27
GR20040100121A (en) 2004-12-17
TNSN05256A1 (en) 2007-07-10
CN101797241B (en) 2013-03-27
DE202004021680U1 (en) 2010-04-22
SI1613288T1 (en) 2009-04-30
NZ592339A (en) 2012-09-28
TW200503784A (en) 2005-02-01
ECSP056090A (en) 2006-03-01
ITMI20040682A1 (en) 2004-07-06
WO2004089341A1 (en) 2004-10-21
DK1613288T3 (en) 2009-03-23
MA27729A1 (en) 2006-01-02
BE2011C030I2 (en) 2023-03-07
GR1005052B (en) 2005-11-30
RU2358716C2 (en) 2009-06-20
GB2400318A (en) 2004-10-13
HRP20100600A2 (en) 2011-03-31
LU91867I2 (en) 2011-11-08
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
US20110105620A1 (en) 2011-05-05
US20190175527A1 (en) 2019-06-13
HRP20100601B1 (en) 2016-12-02
NZ542622A (en) 2009-01-31
AU2004228929B2 (en) 2008-02-07
RU2005134173A (en) 2006-09-10
RU2012148593A (en) 2014-05-20
JP2011006461A (en) 2011-01-13
CN101797241A (en) 2010-08-11
GB0407819D0 (en) 2004-05-12
EP2316431B1 (en) 2015-09-30
RU2475236C2 (en) 2013-02-20
NO335120B1 (en) 2014-09-22
US20200237690A1 (en) 2020-07-30
AR078781A2 (en) 2011-11-30
ES2228282A1 (en) 2005-04-01
NO20055231L (en) 2006-01-09
PL2316431T3 (en) 2016-09-30
AR078782A2 (en) 2011-11-30
NO2011016I2 (en) 2012-08-27
DE602004017847D1 (en) 2009-01-02
IE20040246A1 (en) 2004-12-15
BRPI0409250B1 (en) 2017-07-11
IS2682B (en) 2010-10-15
HUS1100016I1 (en) 2016-08-29
HRP20050886B1 (en) 2011-01-31
US20060275357A1 (en) 2006-12-07
AT501681A1 (en) 2006-10-15
US20170290787A1 (en) 2017-10-12
PE20090743A1 (en) 2009-07-17
US20140011885A1 (en) 2014-01-09
RU2010147000A (en) 2012-08-10
CY2011013I2 (en) 2014-04-09
BRPI0409250B8 (en) 2022-01-18
RU2475237C2 (en) 2013-02-20
MY141249A (en) 2010-03-31
HK1155647A1 (en) 2012-05-25
JP2004307506A (en) 2004-11-04
LU91867I9 (en) 2019-01-03
JP2013177404A (en) 2013-09-09
HRP20050886A2 (en) 2006-11-30
DE122011100047I1 (en) 2011-12-15
SG175449A1 (en) 2011-11-28
EP2008650A3 (en) 2011-04-27
IL170888A (en) 2010-06-16
US8324283B2 (en) 2012-12-04
CY1117071T1 (en) 2017-04-05
HK1091114A1 (en) 2007-01-12
NO2011016I1 (en) 2011-09-19
NO20131287L (en) 2006-01-09
MXPA05010860A (en) 2006-05-25
CN1767819A (en) 2006-05-03
EP2008650A2 (en) 2008-12-31
EP2319502A1 (en) 2011-05-11
CY2011013I1 (en) 2014-04-09
BRPI0409250A (en) 2006-03-28

Similar Documents

Publication Publication Date Title
FR11C0036I2 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL
Giorgi et al. Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs
EP1660043A4 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
DZ3484A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING AN NMDA RECEPTOR AGONIST
IL188980A0 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
ATE354362T1 (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING AN AMORPHIC ACTIVE INGREDIENT
DE60317803D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLOSPORIN FOR ORAL ADMINISTRATION
MA28527B1 (en) ORAL FORMULATIONS CONTAINING LICARBAZEPINE
EA200601015A1 (en) ORAL COMPOSITIONS OF DEOXYPEGANINE AND THEIR APPLICATION
ITMI20061741A1 (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEIN SUBSTANCES
DE112004002737D2 (en) Solvent for biogenic active pharmaceutical ingredients
AR050351A1 (en) COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND PAIN USING A COMBINATION OF AN NSAID AND AN ANTAGONIST OF THE LTB4 RECEIVER
TH70717A (en) Solid pharmaceutical constituents include S1P receptor agonist and sugar alcohol.
TH72202B (en) Solid pharmaceutical constituents include S1P receptor agonist and sugar alcohol.
TH2523A3 (en) Mouthwash products to reduce appetite
ITMI20041849A1 (en) PHARMACEUTICAL FORMULATIONS FOR THE FOOD INTEGRATION OF ANOREXIC SUBJECTS
DK200300002U4 (en) Pharmaceutical formulations containing fluoxetine